Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Minding The Middle: FDA Fleshes Out De Novo Regs As The Program Expands

Executive Summary

A new proposed rule on the de novo classification process does not advance any major policy reforms, but its release underscores the growing popularity of the regulatory pathway that provides flexibility for US FDA and industry in the space between 510(k)s and PMAs.

Advertisement

Related Content

Nudging Firms To Ditch Older Predicates: A Step In US FDA's Planned 510(k) Reforms
FDA's Speedy Apple Watch De Novos Raise Questions For Industry
'Refuse-To-Accept' Policy Outlined For De Novos In New US FDA Draft Guidance
User-Fee Facts: 10 Key Medtech Details From US FDA Agreements
Successful De Novo Petitions Double With Advent Of Direct Route

Topics

Advertisement
UsernamePublicRestriction

Register

MT124327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel